2-(Benzimidazol-2-yl)quinoxalines: A novel class of selective antagonists at human A1 and A3 adenosine receptors designed by 3D database searching

Journal of Medicinal Chemistry

Volumn 48, Issue 26, 2005, Pages 8253-8260

  Novellino, Ettore ^a   Cosimelli, Barbara ^a   Ehlardo, Marina ^a   Greco, Giovanni ^a   Iadanza, Manuela ^a   Lavecchia, Antonio ^a   Rimoli, Maria Grazia ^a   Sala, Annalisa ^a   Da Settimo, Antonio ^b   Primofiore, Giampaolo ^b   Da Settimo, Federico ^b   Taliani, Sabrina ^b   La Motta, Concettina ^b   Klotz, Karl Norbert ^c   Tuscano, Daniela ^b   Trincavelli, Maria Letizia ^b   Martini, Claudia ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 ETHYLTHIOBENZIMIDAZOL 2 YL)QUINOXALINE; 2 (4 METHYLBENZIMIDAZOL 2 YL)QUINOXALINE; 2 (BENZIMIDAZOL 2 YL)QUINOXALINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING KINETICS; DATA BASE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; RECEPTOR BLOCKING;

ADENOSINE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ANIMALS; BENZIMIDAZOLES; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; DATABASES, FACTUAL; DRUG DESIGN; HUMANS; QUINOXALINES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A3; XANTHINES;

EID: 29744457025     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050792d     Document Type: Article

References (44)

1. Wardas, J. Neuroprotective Role of Adenosine in the CNS. Pol. J. Pharmacol. 2002, 54, 313-326.
2. Ribeiro, J. A.; Sebastião, A. M.; de Mendonça, A. Adenosine Receptors in the Nervous System: Pathophysiological Implications. Prog. Neurobiol. (Amsterdam, Neth.) 2003, 68, 377-392.
3. Poulsen, S.-A.; Quinn, R. J. Adenosine Receptors: New Opportunities for Future Drugs. Bioorg. Med. Chem. 1998, 6, 619-641.
4. Rorke, S.; Holgate, S. T. Targeting Adenosine Receptors: Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Am. J. Respir. Med. 2002, 1, 99-105.
5. Nishiyama, A.; Rahman, M.; Inscho, E. W. Role of Interstitial ATP and Adenosine in the Regulation of Renal Hemodynamics and Microvascular Function. Hypertens. Res. 2004, 27, 791-804.
6. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacol. Rev. 2001, 53, 527-552.
7. 1 Adenosine Receptor Ligands. Curr. Top. Med. Chem. 2003, 3, 369-385.
8. Ferre, S.; Fredholm, B. B.; Morelli, M.; Popoli, P.; Fuxe, K. Adenosine-Dopamine Receptor-Receptor Interactions as an Integrative Mechanism in the Basal Ganglia. Trends Neurosci. 1997, 20, 482-487.
9. Franco, R.; Ferre, S.; Agnati, L.; Torvinen, M.; Gines, S.; Hillion, J.; Casado, V.; Lledo, P.; Zoli, M.; Lluis, C.; Fuxe, K. Evidence for Adenosine/Dopamine Receptor Interactions: Indications for Heteromerization. Neuropsychopharmacology 2000, 23, S50-59.
10. 2 Dopamine Receptors in Rat Striatum. Mol. Brain Res. 1992, 14, 186-195.
11. 2A Adenosine Receptor Antagonists. Curr. Top. Med. Chem. 2003, 3, 403-411.
12. 2A Receptors and Therapeutic Applications. Curr. Top. Med. Chem. 2003, 3, 413-426.
13. 3 Receptors: Pharmacological Properties, Species Differences and Receptor Functions. Trends Pharmacol Sci. 1994, 15, 298-306.
14. 3-Adenosine Receptors: Design of Selective Ligands and Therapeutic Prospects. Drugs Future 1995, 20, 689-701.
15. 3 Receptor Ligands. Curr. Top. Med. Chem. 2003, 3, 445-462.
16. 3 Receptor Subtypes. Curr. Top. Med. Chem. 2003, 3, 463-469.
17. Martin, Y. C. 3D Database Searching in Drug Design. J. Med. Chem. 1992, 35, 2145-2154.
18. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Developing Settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
19. Guandalini, L.; Martini, E.; Dei, S.; Manetti, D.; Scapecchi, S.; Teodori, E.; Romanelli, M. N.; Varani, K.; Greco, G.; Spadola, L.; Novellino, E. Design of Novel Nicotinic Ligands through 3D Database Searching. Bioorg. Med. Chem. 2005, 13, 799-807.
20. Enyedy, I. J.; Sakamuri, S.; Zaman, W. A.; Johnson, K. M.; Wang, S. Pharmacophore-Based Discovery of Substituted Pyridines as Novel Dopamine Transporter Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 513-517.
21. Chen, G. S.; Chang, C.-S.; Kan, W. M.; Chang, C.-L.; Wang, K. C.; Chern, J.-W. Novel Lead Generation through Hypothetical Pharmacophore Three-Dimensional Database Searching: Discovery of Isoflavonoids as Nonsteroidal Inhibitors of Rat 5α-Reductase. J. Med. Chem. 2001, 44, 3759-3763.
22. Zaharevitz, D. W.; Gussio, R.; Wiegand, A.; Jalluri, R.; Pattabiraman, N.; Kellogg, G. E.; Pallansch, L. A.; Yang, S. S.; Buckheit, R. W., Jr. Discovery of Novel HIV-1 Reverse Transcriptase Inhibitors Using a Combination of 3D Database Searching and 3D QSAR. J. Med. Chem. 1999, 9, 551-564.
23. 3 Receptor Antagonists. J. Med. Chem. 1999, 42, 3210-3216.
24. Wang, S.; Zaharevitz, D. W.; Sharma, R.; Marquez, V. E.; Lewin, N. E.; Du, L.; Blumberg, P. M.; Milne, G. W. The Discovery of Novel, Structurally Diverse Protein Kinase C Agonists through Computer 3D-Database Pharmacophore Search. Molecular Modeling Studies. J. Med. Chem. 1994, 37, 4479-4489.
25. Allen, F. H.; Bellard, S.; Brice, M. D.; Cartwright, B. A.; Doubleday, A.; Higgs, H.; Hummelimk, T.; Hummelink-Peters, B. G.; Kennard, O.; Motherwell, W. D. S.; Rodgers, J. R.; Watson, D. G. The Cambridge Crystallographic Data Centre: Computer-Based Search, Retrieval, Analysis and Display of Information. Acta Crystallogr., Sect. B: Struct. Sci. 1979, 35, 2231-2239.
26. 6-((R)-Phenylisopropyl)adenosine-Induced Cognitive Disturbance. J. Med. Chem. 1993, 36, 2508-2518.
27. van Galen, P. J. M.; Nissen, P.; van Wijngaarden, I.; IJzerman, A. P.; Soudijn, W. 1H-Imidazo[4,5-c]quinolin-4-amines: Novel Non-Xanthine Adenosine Antagonists. J. Med. Chem. 1991, 34, 1202-1206.
28. 3 Receptor Antagonist. Eur. J. Pharmacol. 2002, 444, 133-141.
29. Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.; Hyun, J. L.; Stone, G. A.; Desai, M.; Williams, M. Structure-Activity Profile of a Series of Novel Triazoloquinazoline Adenosine Antagonists. J. Med. Chem. 1988, 31, 1014-1020.
30. 3 Adenosine Receptor Antagonists. J. Med. Chem. 2002, 45, 770-780.
31. 3 Receptors. J. Med. Chem. 2000, 43, 2227-2238.
32. Bruno, I. J.; Cole, J. C.; Edgington, P. R.; Kessler, M.; Macrae, C. F.; McCabe, P.; Pearson, J.; Taylor, R. New Software for Searching the Cambridge Structural Database and Visualizing Crystal Structures. Acta Crystallogr., Sect. B: Struct. Sci. 2000, 58, 389-397.
33. Kanoktanaporn, S.; MacBride, J. A. H.; King, T. J. Displacement of Hydrazine Hydrochloride from 1,4-Dichlorophthalazines by Bidentate Nucleophiles with Formation of 2,2′-(1,2-Arylene)bis-Benzimidazoles and -Benzothiazoles. X-ray Crystal Structure of 2,3-Bisbenzimidazol-2-ylquinoxaline. J. Chem. Res., Synop. 1980, 12, 406.
34. Prins, R.; Birker, P. J. M. L.; Verschoor, G. C. Structure of 2-[5-(2-Pyridyl)-1H-1,2,4-triazol-3-yl]pyridinium Perchlorate Acta Crystallogr., Sect. B: Struct. Sci. 1982, 38, 2934-2935.
35. Kohne, B.; Praefcke, K.; Derz, T.; Gondro, T.; Frolow, F. Benzenetris(imidazole). A New Ring System from Benzenehexamine. Angew. Chem., Int. Ed. Engl. 1986, 25, 650-651.
36. Heinisch, G.; Matuszczak, B.; Mereiter, K. Pyridazines. 71. A Novel Type of 1,2-Diazine by Ring Contraction of 1,2-Diazole. Heterocycles 1994, 38, 2081-2089.
37. Pecorari, P.; Rinaldi, M.; Costi, M. P.; Antolini, L. Cyclization Reactions of 1,3-Dibromopropan-2-ol, 2,3-Dibromopropan-1-ol and 1-Bromomethyloxirane with 6-Amino-2,3-dihydro-2-thioxo-4(1H)-pyrimidinone. J. Heterocycl. Chem. 1991, 28, 891-898.
38. Mizutani, T.; Yoshida, K.; Kawazoe, S. Formation of Toxic Metabolites from Thiabendazole and Other Thiazoles in Mice. Identification of Thioamides as Ring Cleavage Products. Drug Metab. Dispos. 1994, 22, 750-755.
39. Hay, M. P.; Gamage, S. A.; Kovacs, M. S.; Prujin, F. B.; Anderson, R. F.; Patterson, A. V.; Wilson, W. R.; Brown, J. M.; Denny, W. A. Structure-Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine. J. Med. Chem. 2003, 46, 169-182.
40. 15N-Labeled Hexaaminobenzene Derivatives. Liebigs Ann. Chem. 1991, 691-693.
41. Pecorari, P.; Rinaldi, M.; Costi, M. P. New Heterocyclic Structures. [1,3]Thiazino[3,2-a]purine and [1,2,3]Triazolo[4,5-d][1,3]-thiazino[3,2-a] pyrimidine. J. Heterocycl. Chem. 1989, 26, 1701-1705.
42. Bahner, C. T.; Bilancio, D. E. 5-Thiol-7-hydroxy-1-γ-triazolo[d]- pyrimidine, J. Am. Chem. Soc. 1953, 75, 6038.
43. 1 Adenosine receptor Antagonists, 3-Aryl[1,2,4]triazinobenzimidazol-4-(10H)-ones (ATBIs) and N-alkyl and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): Different Recognition of Bovine and Human Binding Sites. Drug Dev. Res. 2004, 63, 1-7.
44. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.